Xurodopa 110 Tablet combines Levodopa 100mg and Carbidopa 10mg, a widely prescribed therapy for Parkinson’s disease. Levodopa replenishes dopamine levels in the brain, while Carbidopa prevents its premature conversion outside the brain, enhancing efficacy and reducing side effects like nausea.
Belonging to the neurology and CNS segment, Xurodopa 110 is indicated for patients with motor symptoms including tremors, rigidity, and bradykinesia. Its combination formulation ensures improved patient adherence and symptom control.
The tablet is particularly useful in long-term Parkinson’s management, allowing dose titration based on clinical response. Hospitals, neurology clinics, and specialty pharmacies show high demand for this therapy due to its proven effectiveness.
For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Xurodopa 110 Tablet offers a profitable B2B opportunity in the anti-Parkinson segment, providing stable demand and growth potential across India.